Treatment of Anemia in Chronic Kidney Disease: Known, Unknown, and Both

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2012 Jan 31

PMID 22287869

Citations 1

Authors

Robert N Foley

Affiliations

Soon will be listed here.

Abstract

Erythropoiesis is a rapidly evolving research arena and several mechanistic insights show therapeutic promise. In contrast with the rapid advance of mechanistic science, optimal management of anemia in patients with chronic kidney disease remains a difficult and polarizing issue. Although several large hemoglobin target trials have been performed, optimal treatment targets remain elusive, because none of the large trials to date have unequivocally identified differences in primary outcome rates or death rates, and because other reported outcomes indicate the potential for harm (rates of stroke, early requirement for dialysis, and vascular access thrombosis) and benefit (reductions in transfusion requirements and fatigue).

Citing Articles

Artificial Intelligence for the Artificial Kidney: Pointers to the Future of a Personalized Hemodialysis Therapy.

Hueso M, Vellido A, Montero N, Barbieri C, Ramos R, Angoso M Kidney Dis (Basel). 2018; 4(1):1-9.

PMID: 29594137 PMC: 5848485. DOI: 10.1159/000486394.

References

Messana J, Chuang C, Turenne M, Wheeler J, Turner J, Sleeman K . Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis. 2009; 53(3):503-12. DOI: 10.1053/j.ajkd.2008.10.047. View

Semenza G . HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 2001; 107(1):1-3. DOI: 10.1016/s0092-8674(01)00518-9. View

Rossert J, Eckardt K . Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant. 2005; 20(6):1025-8. DOI: 10.1093/ndt/gfh800. View

Stead R, Lambert J, Wessels D, Iwashita J, Leuther K, Woodburn K . Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006; 108(6):1830-4. DOI: 10.1182/blood-2006-04-015818. View

Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T . Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. Am J Kidney Dis. 2007; 50(6):989-1000. DOI: 10.1053/j.ajkd.2007.08.013. View

Locatelli F, Pisoni R, Combe C, Bommer J, Andreucci V, Piera L . Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2003; 19(1):121-32. DOI: 10.1093/ndt/gfg458. View

Egrie J, Browne J . Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 2001; 84 Suppl 1:3-10. PMC: 2363897. DOI: 10.1054/bjoc.2001.1746. View

Besarab A, Bolton W, Browne J, Egrie J, Nissenson A, Okamoto D . The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998; 339(9):584-90. DOI: 10.1056/NEJM199808273390903. View

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

10.

McKoy J, Stonecash R, Cournoyer D, Rossert J, Nissenson A, Raisch D . Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008; 48(8):1754-62. PMC: 2730535. DOI: 10.1111/j.1537-2995.2008.01749.x. View

11.

Bruegge K, Jelkmann W, Metzen E . Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases. Curr Med Chem. 2007; 14(17):1853-62. DOI: 10.2174/092986707781058850. View

12.

Drueke T, Locatelli F, Clyne N, Eckardt K, Macdougall I, Tsakiris D . Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355(20):2071-84. DOI: 10.1056/NEJMoa062276. View

13.

Higuchi M, Kuboniwa H, Tomonoh K, Shimonaka Y, Ochi N . Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem. 1992; 267(11):7703-9. View

14.

Zhu H, BUNN H . Signal transduction. How do cells sense oxygen?. Science. 2001; 292(5516):449-51. PMC: 3040953. DOI: 10.1126/science.1060849. View

15.

Takeuchi M, Kobata A . Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology. 1991; 1(4):337-46. DOI: 10.1093/glycob/1.4.337. View

16.

Nissenson A, Swan S, Lindberg J, Soroka S, Beatey R, Wang C . Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40(1):110-8. DOI: 10.1053/ajkd.2002.33919. View

17.

Yang C, Li C, Jung J, Shin S, Choi B, Lim S . Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003; 17(12):1754-5. DOI: 10.1096/fj.02-1191fje. View

18.

Bernhardt W, Wiesener M, Scigalla P, Chou J, Schmieder R, Gunzler V . Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010; 21(12):2151-6. PMC: 3014028. DOI: 10.1681/ASN.2010010116. View

19.

Canaud B, Mingardi G, Braun J, Aljama P, Kerr P, Locatelli F . Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant. 2008; 23(11):3654-61. PMC: 2568005. DOI: 10.1093/ndt/gfn320. View

20.

Wang G, Semenza G . General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993; 90(9):4304-8. PMC: 46495. DOI: 10.1073/pnas.90.9.4304. View